132 related articles for article (PubMed ID: 23725272)
1. Resistant hypercalcaemia in metastatic parathyroid carcinoma.
Bowyer SE; White AM; Ransom DT; Davidson JA
Med J Aust; 2013 Jun; 198(10):559-61. PubMed ID: 23725272
[No Abstract] [Full Text] [Related]
2. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
[No Abstract] [Full Text] [Related]
3. Denosumab may reduce hypercalcaemia after transplantation for osteopetrosis.
BMJ; 2012 Nov; 345():e7477. PubMed ID: 23135199
[No Abstract] [Full Text] [Related]
4. Denosumab for post-transplantation hypercalcemia in osteopetrosis.
Shroff R; Beringer O; Rao K; Hofbauer LC; Schulz A
N Engl J Med; 2012 Nov; 367(18):1766-7. PubMed ID: 23113501
[No Abstract] [Full Text] [Related]
5. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia.
Vellanki P; Lange K; Elaraj D; Kopp PA; El Muayed M
J Clin Endocrinol Metab; 2014 Feb; 99(2):387-90. PubMed ID: 24178790
[TBL] [Abstract][Full Text] [Related]
6. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.
Cicci JD; Buie L; Bates J; van Deventer H
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e207-11. PubMed ID: 25128013
[No Abstract] [Full Text] [Related]
7. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
8. Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.
Freeman A; El-Amm J; Aragon-Ching JB
Clin Genitourin Cancer; 2013 Dec; 11(4):e24-6. PubMed ID: 24007982
[No Abstract] [Full Text] [Related]
9. Letter to the editor: denosumab for “resistant” hypercalcemia in patients with impaired renal function.
Arampatzis S
J Clin Endocrinol Metab; 2015 Jan; 100(1):L6. PubMed ID: 25559545
[No Abstract] [Full Text] [Related]
10. Is denosumab a long-term option for the treatment of parathyroid carcinoma?
Baretić M
QJM; 2016 Apr; 109(4):288. PubMed ID: 26803154
[No Abstract] [Full Text] [Related]
11. Response to "Is denosumab a long-term option for the treatment of parathyroid carcinoma?".
Tong CV; Hussein Z
QJM; 2016 Apr; 109(4):289. PubMed ID: 26803152
[No Abstract] [Full Text] [Related]
12. Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma.
Nadarasa K; Theodoraki A; Kurzawinski TR; Carpenter R; Bull J; Chung TT; Drake WM
Eur J Endocrinol; 2014 Sep; 171(3):L7-8. PubMed ID: 24939719
[No Abstract] [Full Text] [Related]
13. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
14. Denosumab for tumor-induced hypercalcemia complicated by renal failure.
Bech A; de Boer H
Ann Intern Med; 2012 Jun; 156(12):906-7. PubMed ID: 22711097
[No Abstract] [Full Text] [Related]
15. Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma.
Makino H; Notsu M; Asayama I; Otani H; Morita M; Yamamoto M; Yamauchi M; Nakao M; Miyake H; Araki A; Uchino S; Kanasaki K
Intern Med; 2022 Nov; 61(22):3383-3390. PubMed ID: 35370235
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
17. Stilboestrol diphosphate in hypercalcaemia due to parathyroid carcinoma.
Sigurdsson G; Woodhouse NJ; Taylor S; Joplin GF
Br Med J; 1973 Jan; 1(5844):27-8. PubMed ID: 4683634
[No Abstract] [Full Text] [Related]
18. Pathologic quiz case: recurrent hypercalcemia.
Jaffey P; Kahky M; Ackerman E
Arch Pathol Lab Med; 2000 Jul; 124(7):1087-8. PubMed ID: 10888790
[No Abstract] [Full Text] [Related]
19. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
Booth KA; Hays CI
J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
[TBL] [Abstract][Full Text] [Related]
20. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
